A new framework aims to extend organoid technology into immuno-oncology, mechanistic research, drug discovery, and precision clinical decision support by creating more faithful tumor models and enabling predictive testing.

Clinical translation faces challenges such as time to establish cultures, cost and labor, variable engraftment across tumor types, lack of standardized procedures, and the need for prospective validation, with adoption hinging on standardization, automation, AI-driven data integration, and ethical frameworks.

Conventional organoid culture lacks the tumor microenvironment, spatial heterogeneity, and dynamic physiological cues, which limits modeling of immune responses, metabolism, and resistance, and raises reproducibility concerns.

To address these gaps, the authors propose a four-layer functional integration framework: genetic engineering with CRISPR to test mutations; expanding the cellular ecosystem through co-cultures and air–liquid interfaces to include fibroblasts, endothelial and mesenchymal cells, and immune components; enhancing spatial architecture via single-cell and spatial multi-omics plus 3D bioprinting to recreate tumor geography; and implementing organ-on-a-chip systems to model perfusion, gradients, pharmacokinetics, and multi-tissue interactions.

Tumor organoids are patient-derived 3D cultures that preserve genetic heterogeneity and phenotype, enabling functional drug sensitivity testing that can mirror clinical outcomes.

The article envisions a functional digital twin that combines organoids with computational models to rehearse treatments, predict resistance, and adapt to tumor evolution, contingent on advances in standardization and data integration.

Applications span mechanistic studies of EMT and metabolic reprogramming, high-content, patient-relevant drug screening, immunotherapy modeling (including checkpoint inhibitors, CAR-T, and bispecifics), and serving as avatars to guide neoadjuvant therapy decisions across multiple cancers.